Abstract:Introduction: Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) played a key role in monitoring therapeutic efficacy and predicting prognosis for patients with acute myeloid leukemia (AML). However, identifying optimal assessing time points and incorporating MRD with other response criteria are inconclusive. Herein, based on our patient cohort data, we investigated the effect of early MRD on outcome of AML patients with different genetic-risk group and further evaluated its' impact on the allogeneic stem cell transplantation (Allo-HSCT) decision-making, which will help to establish an overall dynamic stratified prognosis system at the MRD level. Methods: Retrospective study was conducted in patients with newly diagnosed de novo AML (acute promyeloid leukemia exclude) in three clinical trials (ChiCTR-TRC-10001202 trial, ChiCTR-TRC-10001209 trial, and NCT03021330). Patients under age 60 who achieved morphological complete remission (CR) within two courses of chemotherapy were enrolled in our study. Any detectable MRD by LAIP and/or different-from-normal were reported as MFC-MRD positive. We firstly investigated the relapse and survival of patients with different MFC-MRD status after the first course (C1) or second course (C2). Then, the outcome of incorporate MRD status in AML patients with different genetic-risk classification were evaluated. And the outcome of Allo-HSCT during the first CR and its association with the MRD status were also analyzed. Result: The pooled analysis included 769 patients, with a median age of 38 (range 14 to 60). According to ELN 2017 recommendation, 427 (55.5%), 230 (29.9%), and 112 (14.6%) patients were classified as favorable (FR), intermediate (IR), and adverse (AR) risk groups, respectively. By evaluating relapse and survival based on MRD status, MRD positivity after C1 and C2 were both associated with significantly higher 3-year CIR (C1: 44.6% MRD+ vs. 28.3% MRD-, P < 0.001; C2 53.5% MRD+ vs. 31.0% MRD-, P < 0.001), poor RFS (47.0% vs. 66.9%, P < 0.001; 41.0% vs. 63.0%, P < 0.001) and OS (52.5% vs. 78.6%, P < 0.001; 48.0% vs. 75.6%, P < 0.001). Hierarchical analysis revealed that after C1, MRD positivity related to significantly worse prognosis in each risk group. In FR group, CRMRD+ patients exhibited higher relapse rate compared to CRMRD- patients (3-year CIR, 34.5% vs. 23.1%, P = 0.077), as well as worse survival (3-year OS, 71.0% vs. 85.8%, P = 0.007). Similarly, in IR group, 3-year CIR was 47.2% in CRMRD+ compared to 36.0% in CRMRD- (P = 0.009), along with a worse 3-year OS (47.8% vs. 72.9%, P < 0.001). And the trend remained consistent in the AR group (CIR, 62.6% CRMRD+ vs. 37.1% CRMRD-, P = 0.026; OS, 21.2% vs. 55.5%, P = 0.002). This disadvantage became more apparent after C2, especially in FR (CIR, 40.7% CRMRD+ vs. 25.2% CRMRD-, P = 0.019; OS, 57.6% vs. 84.0%, P < 0.001) and IR (CIR, 61.5% vs. 35.2%, P < 0.001; OS, 44.2% vs. 70.7%, P < 0.001). 223 patients received Allo-HSCT during their CR1, 89 (39.9%), 81 (36.3%), and 53 (23.8%) patients were from FR, IR, and AR groups, respectively. Through landmark analysis and time-dependent Cox proportional hazards regression, we demonstrated that the outcome of patients with CRMRD+, particularly in FR and IR groups, was significantly improved by means of Allo-HSCT. In FR group after C2, OS of CRMRD+ patients was prolonged by Allo-HSCT during CR1 (HR, 0.383, [0.201~0.731], P = 0.004) (Figure B). In IR group, the OS of CRMRD+ patients after C1 were improved after allo-HSCT (HR, 0.529, [0.329~0.849], P = 0.008) (Figure A). Similar trend was also witnessed after C2 (HR, 0.467, [0.277~0.786], P = 0.004) (Figure B). However, OS of CRMRD- patients in FR and IR group were comparable between transplant and non-transplant patients. In AR group, regardless of MRD status, all patients could be benefited from allo-HSCT. Conclusion: Early MRD clearance exhibited great prognostic significance, especially for patients in the favorable and intermediate risk group. Meanwhile, MRD positivity after C1 and C2 could early identify patients who need CR1 allo-HSCT in the intermediate risk group. And for patients in the favorable risk group, the evaluation time for Allo-HSCT decision-making should be after C2. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study

Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia

Superiority of Leukemic Stem Cell-Based Minimal Residual Disease Assay to Traditional Multiparameter Flow Cytometry-Based Method for Relapse Prediction in AML Patients: A Prospective Study with Randomized Training and Validation Sets

Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia

Different Minimal Residual Disease Levels Between Childhood Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Detected with Multi-Parameter Flow Cytometry.

Long-Term Follow Up of Chinese Children with Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Detection

[Prognostic Significance of Minimal Residual Disease Detected by Multiparameter Flow Cytometry in Acute Myeloid Leukemia].

Prognostic Significance of Flow Cytometric Minimal Residual Disease Assessment after the First Induction Course in Chinese Childhood Acute Myeloid Leukemia

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation

Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

[Monitoring of Minimal Residual Disease in Children with Acute Lymphoblastic Leukemia and Its Prognostic Significance].

Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.

Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance

Measurable Residual Disease Testing by Next Generation Sequencing is More Accurate Compared with Multiparameter Flow Cytometry in Adults with B-cell Acute Lymphoblastic Leukemia

New Assay Technology and Utility of Peripheral Blood Vs Bone Marrow for Molecular MRD in AML and MDS

Measurable Residual Disease Monitoring by Ddpcr in the Early Posttransplant Period Complements the Traditional MFC Method to Predict Relapse after HSCT in AML/MDS: a Multicenter Retrospective Study.

Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study

P383: the next-generation sequencing (ngs) based mrd assessment could better predict relapse than multiparameter flow cytometry (mfc) in adult b-cell acute lymphoblastic leukemia

Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations

Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)